ARC

Study aims to correlate pharmacokinetic(PK)/pharmacodynamic profiles of three ß-lactams with renal function in patients with malignancy and infection, and elaborate optimal dosing recommendation using population PK and modelling. 144 patients from 6 months to 25 years with cancer receiving treatment with cefepime, piperacillin-tazobactam or meropenem and calculated glomerular filtration rate > 80 ml/min/1.73 m2 will be eligible. Renal function will be assessed by iohexol clearance. Based on the results we expect to describe the prevalence of ARC in study population and elaborate specific dosing recommendation to optimize treatment efficacy.